Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Actinium Pharmaceuticals Inc
(NY:
ATNM
)
7.370
+0.210 (+2.93%)
Official Closing Price
Updated: 8:00 PM EDT, Jun 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
194,577
Open
7.150
Bid (Size)
7.200 (3)
Ask (Size)
8.000 (1)
Prev. Close
7.160
Today's Range
7.000 - 7.430
52wk Range
4.000 - 10.24
Shares Outstanding
21,331,314
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
June 18, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and...
Via
Newsfile
Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
June 18, 2024
Via
AB Newswire
Performance
YTD
+38.53%
+38.53%
1 Month
-10.34%
-10.34%
3 Month
-7.18%
-7.18%
6 Month
+39.58%
+39.58%
1 Year
+1.38%
+1.38%
More News
Read More
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
Via
FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
Via
FinancialNewsMedia
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
June 17, 2024
Via
Newsfile
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
June 17, 2024
Via
FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
June 17, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
June 10, 2024
Via
InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
June 07, 2024
Via
InvestorPlace
3 Cheap Biotech Stocks to Buy Now: May 2024
May 14, 2024
Via
InvestorPlace
Exposures
Product Safety
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
May 09, 2024
Via
AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
May 08, 2024
Via
AB Newswire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
April 29, 2024
Via
InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
Via
Investor's Business Daily
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
April 19, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
April 17, 2024
Via
AB Newswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
April 15, 2024
Via
InvestorPlace
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
March 28, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
March 27, 2024
Via
AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
March 26, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
March 22, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
March 21, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
March 20, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.